1. Home
  2. SCOR vs SCYX Comparison

SCOR vs SCYX Comparison

Compare SCOR & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCOR
  • SCYX
  • Stock Information
  • Founded
  • SCOR 1999
  • SCYX 1999
  • Country
  • SCOR United States
  • SCYX United States
  • Employees
  • SCOR N/A
  • SCYX N/A
  • Industry
  • SCOR Business Services
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SCOR Consumer Discretionary
  • SCYX Health Care
  • Exchange
  • SCOR Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • SCOR 34.6M
  • SCYX 34.9M
  • IPO Year
  • SCOR 2007
  • SCYX 2014
  • Fundamental
  • Price
  • SCOR $6.41
  • SCYX $1.06
  • Analyst Decision
  • SCOR
  • SCYX
  • Analyst Count
  • SCOR 0
  • SCYX 0
  • Target Price
  • SCOR N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • SCOR 7.6K
  • SCYX 205.0K
  • Earning Date
  • SCOR 11-11-2025
  • SCYX 11-05-2025
  • Dividend Yield
  • SCOR N/A
  • SCYX N/A
  • EPS Growth
  • SCOR N/A
  • SCYX N/A
  • EPS
  • SCOR N/A
  • SCYX N/A
  • Revenue
  • SCOR $358,513,000.00
  • SCYX $3,257,000.00
  • Revenue This Year
  • SCOR $3.45
  • SCYX $422.61
  • Revenue Next Year
  • SCOR $2.59
  • SCYX $240.56
  • P/E Ratio
  • SCOR N/A
  • SCYX N/A
  • Revenue Growth
  • SCOR N/A
  • SCYX N/A
  • 52 Week Low
  • SCOR $4.39
  • SCYX $0.66
  • 52 Week High
  • SCOR $8.99
  • SCYX $1.66
  • Technical
  • Relative Strength Index (RSI)
  • SCOR 51.69
  • SCYX 65.49
  • Support Level
  • SCOR N/A
  • SCYX $0.81
  • Resistance Level
  • SCOR $6.92
  • SCYX $1.31
  • Average True Range (ATR)
  • SCOR 0.18
  • SCYX 0.07
  • MACD
  • SCOR -0.28
  • SCYX 0.02
  • Stochastic Oscillator
  • SCOR 91.97
  • SCYX 50.40

About SCOR comScore Inc.

comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each across media platforms. The platforms it measures include televisions, mobile devices, computers, tablets, CTV devices, and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada, and other regions. It provides solutions for the automotive, digital media, financial services, pharmaceutical, retail, technology, travel, and other industries.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: